A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Atezolizumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KATE2
- Sponsors Roche
- 01 Dec 2017 Planned End Date changed from 29 Aug 2019 to 13 Jan 2021.
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Aug 2017 Planned End Date changed from 5 Jun 2019 to 29 Aug 2019.